x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Jul2026

A New Chapter: Ariana Pharma Appoints Thomas Turcat as Chief Executive Officer

Ariana Pharma announces the appointment of Thomas Turcat as Chief Executive Officer

The transition marks a new chapter for Ariana Pharma as it expands the reach of its explainable AI technology with in-house drug development expertise to transform small, heterogeneous clinical cohorts into regulatory-ready results that are logical and rule-association-based while leveraging Thomas’ broad commercial expertise. The output is transparent and explainable, giving research teams evidence they can understand, challenge, and act on.
Thomas Turcat brings more than 15 years of experience leading technology companies at the intersection of AI and healthcare, with full P&L responsibility for fast-growing ventures. He was previously CEO of OmiCure, an AI-driven tumor-profiling platform, and earlier held strategy roles at Roland Berger and AT Kearney. He takes on the role of CEO as Ariana Pharma enters its next phase of growth, adding flexibility in the business model, increasing the value brought to biotech and pharmaceutical partners.
“Having experienced the realities of drug development, I have seen firsthand how too many promising programs fail because of suboptimal trial design and an incomplete understanding of complex data. At Ariana Pharma, our mission is to improve the success rate of drug development by combining explainable AI with deep scientific and clinical expertise, delivering insights researchers can trust and act on with confidence. As I step into this role, my ambition is to scale our technology, embrace the latest advances in AI, and further strengthen the scientific and clinical excellence that sets Ariana apart. As we grow, preserving our collaborative, science-first culture will remain just as important as advancing our technology, because it is our people and the way we work together, that drive innovation and create lasting value for our partners. Together, we have a unique opportunity to transform how drug development decisions are made, helping our partners move faster, reduce uncertainty, and bring life-changing therapies to patients.”
Press Release

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved